Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GMAB   DK0010272202

GENMAB

(GMAB)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/11/2019 11/12/2019 11/13/2019 11/14/2019 11/15/2019 Date
1504(c) 1491.5(c) 1508(c) 1490.5(c) 1506.5(c) Last
207 332 127 346 224 484 180 738 176 441 Volume
+0.40% -0.83% +1.11% -1.16% +1.07% Change
More quotes
Financials (DKK)
Sales 2019 5 042 M
EBIT 2019 2 393 M
Net income 2019 2 063 M
Finance 2019 10 175 M
Yield 2019 -
Sales 2020 5 693 M
EBIT 2020 2 507 M
Net income 2020 2 104 M
Finance 2020 11 322 M
Yield 2020 -
P/E ratio 2019 47,2x
P/E ratio 2020 43,6x
EV / Sales2019 17,4x
EV / Sales2020 15,2x
Capitalization 98 035 M
More Financials
Company
Genmab specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (57.6%); - income from research and development (22.7%); - other... 
Sector
Biotechnology & Medical Research
Calendar
12/09 | 08:00pmR&D Day
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
11/14GENMAB A/S : has published its Articles of Association
AQ
11/12GENMAB : Transactions with shares and linked securities in Genmab A/S made by ma..
AQ
11/12GENMAB : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/12GENMAB : Admission of new securities
CO
11/06GENMAB : Interim Report for the First Nine Months of 2019
PU
11/06Genmab Announces Financial Results for the First Nine Months of 2019
GL
11/06GENMAB : Announces Data to be Presented at 2019 ASH Annual Meeting
AQ
11/01GENMAB A/S : quaterly earnings release
10/31GENMAB : Financial Calendar for 2020
AQ
10/30David Eatwell to Retire as Chief Financial Officer of Genmab
GL
10/30GENMAB : Financial Calendar for 2020
AQ
10/29GENMAB : Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exch..
PU
10/23GENMAB A/S : has published its Articles of Association
AQ
10/21GENMAB : CHMP Issues Positive Opinion Recommending DARZALEX in Combination with ..
AQ
10/18JOHNSON & JOHNSON : Genmab, Janssen Get CHMP Positive Option for Expanded Darzal..
DJ
More news
News in other languages on GENMAB
11/01GENMAB A/S : Veröffentlichung des Quartalsergebnisses
11/01GENMAB A/S : publication des résultats trimestriels
10/15EN DIRECT DES MARCHES : Air France KLM, Alstom, LVMH, CGG, General Motors, Bo..
10/15STOCK MARKET PARIS : Pompier pyromane ?
10/14Lonza und Genmab bauen Zusammenarbeit aus
More news
Analyst Recommendations on GENMAB
More recommendations
Sector news : Bio Therapeutic Drugs
11/14BEIGENE : FDA Gives Accelerated Approval to BeiGene's Brukinsa
DJ
11/14Walt Disney soars while Cisco disappoints
11/14THERMO FISHER SCIENTIFIC : Qiagen Shares Surge on Report Thermo Fisher Mulling D..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
More sector news : Bio Therapeutic Drugs
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 1 517,63  DKK
Last Close Price 1 506,50  DKK
Spread / Highest target 33,3%
Spread / Average Target 0,74%
Spread / Lowest Target -38,3%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
Michael K. Bauer SVP, Head-Operations, Research & Development
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Non-Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB39.63%14 493
GILEAD SCIENCES4.03%82 323
VERTEX PHARMACEUTICALS26.61%53 950
REGENERON PHARMACEUTICALS-7.67%37 702
WUXI APPTEC CO., LTD.81.65%22 459
BEIGENE, LTD.41.34%12 019